Detalhe da pesquisa
1.
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Future Oncol
; 18(29): 3245-3254, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950603
2.
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats.
Int J Med Sci
; 19(11): 1628-1630, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36237984
3.
What Exactly Is Inflammation (and What Is It Not?).
Int J Mol Sci
; 23(23)2022 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499232
4.
RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Int J Mol Sci
; 22(9)2021 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33946824
5.
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Mol Pharm
; 16(7): 2929-2934, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31038318
6.
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Future Oncol
; 15(30): 3427-3433, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31509028
7.
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
J Cell Mol Med
; 22(10): 5076-5082, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010241
8.
TGF-ß: the apex predator of immune checkpoints.
Future Oncol
; 19(30): 2013-2015, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37503560
9.
RRx-001, A novel dinitroazetidine radiosensitizer.
Invest New Drugs
; 34(3): 371-7, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26841903
10.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952
11.
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.
Malar J
; 14: 218, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26017006
12.
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.
Biochem Biophys Res Commun
; 447(3): 537-42, 2014 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735538
13.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther
; 31(4): 517-526, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146006
14.
Commentary on oncolytic viruses: past, present, and future.
J Immunother Cancer
; 11(12)2023 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135348
15.
Patent and Marketing Exclusivities 101 for Drug Developers.
Recent Pat Biotechnol
; 17(3): 257-270, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635930
16.
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.
Front Oncol
; 13: 1204143, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37313460
17.
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Front Oncol
; 13: 1176448, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342189
18.
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).
Front Immunol
; 14: 1104753, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36960054
19.
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient.
Case Rep Oncol
; 16(1): 172-176, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37008834
20.
A Review of Persistent Post-COVID Syndrome (PPCS).
Clin Rev Allergy Immunol
; 64(1): 66-74, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609255